Leiv Lea - 06 Dec 2023 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Chief Financial Officer
Signature
/s/ Leiv Lea
Issuer symbol
CRVS
Transactions as of
06 Dec 2023
Net transactions value
$0
Form type
4
Filing time
08 Dec 2023, 16:08:13 UTC
Previous filing
15 Dec 2022
Next filing
23 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 06 Dec 2023 Common Stock 200,000 $1.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.